Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

The response rate in the control cohort is in line with historical data on azacitidine. Investors, already burnt by setbacks ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...

Data presentations will focus on the company's clinical and preclinical studies in IDH-mutated acute myeloid leukemia (AML) ...